Hyperuricemia studies call for validated, thorough in vivo models.

Hyperuricemia can be divided into primary hyperuricemia (usually due to an increased production of uric acid from purine or due to the kidneys malfunctioning) and secondary hyperuricemia. The latter can be caused by a multitude of factors and diseases, notably certain cancers and chemotherapy agents that markedly increase the turnover rate of cell death.

Clinically relevant HUA models are critical for the development of better treatments, so having access to these models, as well as working with a CRO with unrivaled knowledge and skills in preclinical pharmacology, is pivotal for the outcome of your candidates. Contact us at PharmaLegacy so that we discuss the next step in your preclinical HUA studies.

Contact Us


Pioneering healthcare solutions:

  • Electronically managed, traceable research data
  • PK/PD, molecular pharmacology and preliminary toxicology adjacency studies
  • 24/7 access to PharmaLegacy representatives
  • Capacity to house over 30,000 rodents and large animals

At PharmaLegacy, we bridge basic research and clinical reality. Contact us now to turn your research into a clinical reality.

Contact Us

We’re ready when you are.

Tell us your pharmacology challenges.